ReviewGene therapy2012
Cardiac gene therapy in large animals: bridge from bench to bedside.
Review in Gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cardioprotection in cardiovascular surgery.Basic research in cardiology · 2024Review
- Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them.Heart, lung & circulation · 2023Article
- Transthoracic ultrasound-guided percutaneous intramyocardial injection combined with ultrasound-targeted microbubble destruction-mediated angiogenin 1 gene therapy in canine myocardial infarction model.Cardiovascular diagnosis and therapy · 2021Article
- Targeted delivery of therapeutic agents to the heart.Nature reviews. Cardiology · 2021Review
- Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.Heart failure reviews · 2019Review
- Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery.Gene therapy · 2019Article
- Development of a Novel Large Animal Model to Evaluate Human Dental Pulp Stem Cells for Articular Cartilage Treatment.Stem cell reviews and reports · 2018Article
- SERCA control of cell death and survival.Cell calcium · 2018Review
- Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction.Handbook of experimental pharmacology · 2017Review
- Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy.JACC. Basic to translational science · 2016Article
- Gene therapy for the treatment of heart failure: promise postponed.European heart journal · 2016Review
- Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions.American journal of physiology. Heart and circulatory physiology · 2014Article
- Brazilian minipig as a large-animal model for basic research and stem cell-based tissue engineering. Characterization and in vitro differentiation of bone marrow-derived mesenchymal stem cells.Journal of applied oral science : revista FOB · 2014Article
- Heart failure gene therapy: the path to clinical practice.Circulation research · 2013Review
- Percutaneous approaches for efficient cardiac gene delivery.Journal of cardiovascular translational research · 2013Review
- Potential of gene therapy as a treatment for heart failure.The Journal of clinical investigation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several clinical trials are evaluating gene transfer as a therapeutic approach to treat cardiac diseases. Although it has just started on the path to clinical application, recent advances in gene delivery technologies with increasing knowledge of underlying mechanisms raise great expectations for the cardiac gene therapy. Although in vivo experiments using small animals provide the therapeutic potential of gene transfer, there exist many fundamental differences between the small animal and the human hearts. Before applying the therapy to clinical patients, large animal studies are a prerequisite to validate the efficacy in an animal model more relevant to the human heart. Several key factors including vector type, injected dose, delivery method and targeted cardiac disease are all important factors that determine the therapeutic efficacy. Selecting the most optimal combination of these factors is essential for successful gene therapy. In addition to the efficacy, safety profiles need to be addressed as well. In this regard, large animal studies are best suited for comprehensive evaluation at the preclinical stages of therapeutic development to ensure safe and effective gene transfer. As the cardiac gene therapy expands its potential, large animal studies will become more important to bridge the bench side knowledge to the clinical arena.
Indexed as
Identifiers
22301438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.